STOCK TITAN
  1. Home
  2. Sec-filings
  3. RAPT
  4. [EFFECT] RAPT Therapeutics, Inc. SEC Filing

[EFFECT] RAPT Therapeutics, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: March 4, 2026
Accession Number: 0001193125-26-088293
Submission Type: POS AM
CIK: 0001673772
Company Name: RAPT Therapeutics, Inc.
File Number: 333-284388

Source: View Original Filing on SEC EDGAR

Rapt Therapeutics, Inc.

NASDAQ:RAPT

View RAPT Stock Overview →

RAPT Rankings

#2315 Ranked by Market Cap
N/A Ranked by Dividends

RAPT Latest News

Jan 7, 2026
RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Nov 6, 2025
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Nov 4, 2025
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
Oct 27, 2025
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
Oct 21, 2025
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

RAPT Latest SEC Filings

Mar 18, 2026
[15-12G] RAPT Therapeutics, Inc. SEC Filing
Mar 5, 2026
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity
Mar 5, 2026
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity
Mar 5, 2026
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity
Mar 5, 2026
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

RAPT Stock Data

1.68B
23.85M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO